The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy

PCSK9 inhibitors (PCSK9i) are monoclonal antibodies that have been shown to be effective in reducing both LDL cholesterol (LDL-C) values and major cardiovascular events in patients at high cardiovascular risk. Adherence to PCSK9i is critical for the success of the treatment. The aim of the present study is to evaluate patients’ adherence to PCSK9i during the COVID-19 pandemic. Patients referred to the Cardiac Diagnostic Unit of the University of Campania “Luigi Vanvitelli” Naples, taking PCSK9i, and who missed the cardiological follow-up visit during the first national COVID-19 lockdown (9 March–17 May 2020), were included. Each patient underwent medical teleconsultation to collect current clinical conditions, adherence to drug treatments, and lipid profile laboratory tests. Among 151 eligible patients, 20 were excluded for missing or untraceable telephone numbers and one for refusing to join the interview. The selected study population consisted of 130 patients (64 ± 9 years, 68% males), of whom 11 (8.5%) reported a temporary interruption of the PCSK-9 therapy for a mean period of 65 ± 1.5 days. The non-adherent patients showed a marked increase in LDL-C than in the pre-pandemic period (90.8 ± 6.0 vs. 54.4 ± 7.7 mg/dL, p < 0.0001), and 82% of patients moved out of the LDL-C therapeutic range. The non-adherent group was more likely to have a very high cardiovascular risk compared to the adherent group (81.8 vs. 33.6%, p < 0.001). Causes of interruption included drug prescription failure (63.6%) due to temporary interruption of the non-urgent outpatient visits and failure in drug withdrawal (36.4%) due to patients’ fear of becoming infected during the pandemic. The COVID-19 lockdown caused a remarkable lack of adherence to PCSK9i therapy, risking negative implications for the health status of patients at high cardiovascular risk. Facilitating patients’ access to PCSK9i and enhancing telemedicine seem to be effective strategies to ensure the continuity of care and appropriate management of these patients.

[1]  D. Carretta,et al.  The Impact of COVID-19 Outbreak on Syncope Units Activities in Italy: A Report from the Italian Multidisciplinary Working Group on Syncope (GIMSI) , 2021, International journal of environmental research and public health.

[2]  A. Fiorelli,et al.  Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic , 2021, International journal of environmental research and public health.

[3]  A. Rapacciuolo,et al.  Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown , 2021, European heart journal. Digital health.

[4]  A. Rapacciuolo,et al.  Cardiac pacing procedures during coronavirus disease 2019 lockdown in Southern Italy: insights from Campania Region , 2021, Journal of cardiovascular medicine.

[5]  G. Cimmino,et al.  Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization , 2020, International journal of environmental research and public health.

[6]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[7]  A. Rapacciuolo,et al.  Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown , 2020, Expert review of medical devices.

[8]  P. Golino,et al.  COVID-19 and Heart: From Clinical Features to Pharmacological Implications , 2020, Journal of clinical medicine.

[9]  R. de Caterina,et al.  Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era , 2020, European heart journal.

[10]  Elham Monaghesh,et al.  The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence , 2020, BMC Public Health.

[11]  J. H. Gittell,et al.  From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak? , 2020, medRxiv.

[12]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[13]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[14]  Odyssey Outcomes Investigators Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[15]  G. Limongelli,et al.  Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience , 2017, Journal of cardiovascular medicine.

[16]  R. Krauss,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .

[17]  Lawrence A Leiter,et al.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[18]  Christian Sperber,et al.  An upper and lower bound of the Medication Possession Ratio , 2017, Patient preference and adherence.

[19]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[20]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[21]  R. Giugliano,et al.  Cognitive Function in a Randomized Trial of Evolocumab. , 2017, The New England journal of medicine.

[22]  T. McCormack,et al.  Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date , 2016, International journal of clinical practice.

[23]  Paul M Ridker,et al.  Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). , 2011, Journal of the American College of Cardiology.

[24]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[25]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[26]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[27]  W. Howard Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .